Isofol Medical AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ISOFOL.ST research report →
Companyisofolmedical.com
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital.
- CEO
- Petter Segelman Lindqvist
- IPO
- 2017
- Employees
- 5
- HQ
- Gothenburg, SE
Price Chart
Valuation
- Market Cap
- $233.00M
- P/E
- -3.68
- P/S
- 0.00
- P/B
- 2.20
- EV/EBITDA
- -3.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.93%
- ROIC
- -61.30%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-54,168,000 · -24.56%
- EPS
- $-0.25 · 7.41%
- Op Income
- $-54,761,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $1.74
- 52W Low
- $0.55
- 50D MA
- $0.68
- 200D MA
- $0.72
- Beta
- 0.32
- Avg Volume
- 1.72M
Get TickerSpark's AI analysis on ISOFOL.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ISOFOL.ST Coverage
We haven't published any research on ISOFOL.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ISOFOL.ST Report →